,drugs in development,Net present value in billion U.S. dollars
0,Ide-Cel (acquired),6.2
1,Risdiplam (in-licensed),5.3
2,Valoctocogene Roxaparvovec  (in-licensed),5.1
3,Efgartigimod (organic),4.3
4,Liso-Cel  (acquired),4.2
5,Selpercatinib (acquired),4.1
6,Belantamab Mafodotin  (organic),3.8
7,Ripretinib  (organic),3.1
8,Tafasitamab (in-licensed),2.8
9,Lenabasum (in-licensed),2.7
